Trade Report: Today, Victory Capital Management Inc. Raises its position in Celgene Corp. (CELG) as a favorable investment target.

Today, Victory Capital Management Inc. Raises its position in Celgene Corp. (CELG) as a favorable investment target.

Victory Capital Management Inc. increased its position in shares of Celgene Corp. (NASDAQ:CELG) by 27.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 724,953 shares of the biopharmaceutical company’s stock after buying an additional 158,297 shares during the period. Victory Capital Management Inc. owned 0.09% of Celgene Corp. worth $75,779,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of CELG. First Financial Corp IN raised its stake in shares of Celgene Corp. by 30.9% in the third quarter. First Financial Corp IN now owns 967 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 228 shares in the last quarter. Jolley Asset Management LLC raised its stake in shares of Celgene Corp. by 58.8% in the second quarter. Jolley Asset Management LLC now owns 1,215 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 450 shares in the last quarter. Smithfield Trust Co. raised its stake in shares of Celgene Corp. by 12.5% in the second quarter. Smithfield Trust Co. now owns 1,282 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 142 shares in the last quarter. Integrated Investment Consultants LLC raised its stake in shares of Celgene Corp. by 21.8% in the second quarter. Integrated Investment Consultants LLC now owns 1,339 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 240 shares in the last quarter. Finally, Cornerstone Advisors Inc. raised its stake in shares of Celgene Corp. by 202.8% in the third quarter. Cornerstone Advisors Inc. now owns 1,320 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 884 shares in the last quarter. 77.85% of the stock is owned by institutional investors and hedge funds.

Shares of Celgene Corp. (NASDAQ:CELG) traded up 0.17% during midday trading on Friday, reaching $121.06. 1,792,549 shares of the company’s stock traded hands. The stock has a market cap of $93.85 billion, a P/E ratio of 45.98 and a beta of 1.71. The stock has a 50 day moving average of $107.85 and a 200-day moving average of $106.38. Celgene Corp. has a 12 month low of $93.05 and a 12 month high of $127.00.

Celgene Corp. (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.48 by $0.10. The business earned $2.98 billion during the quarter, compared to analysts’ expectations of $2.84 billion. Celgene Corp. had a net margin of 19.71% and a return on equity of 70.48%. The business’s quarterly revenue was up 27.8% on a year-over-year basis. During the same period last year, the company posted $1.23 earnings per share. On average, equities research analysts forecast that Celgene Corp. will post $5.92 EPS for the current fiscal year.

A number of brokerages recently weighed in on CELG. Argus reissued a “buy” rating and issued a $155.00 price target on shares of Celgene Corp. in a report on Wednesday, September 7th. Cowen and Company reaffirmed a “buy” rating and set a $150.00 target price on shares of Celgene Corp. in a report on Thursday, July 28th. Leerink Swann reaffirmed a “market perform” rating and set a $135.00 target price on shares of Celgene Corp. in a report on Monday, September 12th. Stifel Nicolaus reaffirmed a “buy” rating and set a $138.00 target price on shares of Celgene Corp. in a report on Tuesday, August 2nd. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Celgene Corp. in a report on Tuesday, October 18th. Four research analysts have rated the stock with a hold rating and twenty-five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $136.30.

In other Celgene Corp. news, Director Michael A. Friedman sold 18,600 shares of the firm’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $116.10, for a total value of $2,159,460.00. Following the transaction, the director now directly owns 18,600 shares of the company’s stock, valued at $2,159,460. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard W. Barker sold 20,000 shares of the firm’s stock in a transaction on Friday, September 23rd. The shares were sold at an average price of $110.82, for a total transaction of $2,216,400.00. Following the completion of the transaction, the director now directly owns 31,332 shares in the company, valued at $3,472,212.24. The disclosure for this sale can be found here. 0.97% of the stock is currently owned by company insiders.

Celgene Corp. Company Profile

Related posts

Leave a Comment